|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Di Cristofano A and Ellenson LH:
Endometrial carcinima. Annu Rev Pathol. 2:57–85. 2007. View Article : Google Scholar
|
|
3
|
Salvesen HB, Haldorsen IS and Trovik J:
Markers for individualised therapy in endometrial carcinoma. Lancet
Oncol. 13:e353–e361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kong YY, Yoshida H, Sarosi I, Tan HL,
Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G,
Itie A, et al: OPGL is a key regulator of osteoclastogenesis,
lymphocyte development and lymph-node organogenesis. Nature.
397:315–323. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fata JE, Kong YY, Li J, Sasaki T,
Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey
DL, et al: The osteoclast differentiation factor
osteoprotegerin-ligand is essential for mammary gland development.
Cell. 103:41–50. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beleut M, Rajaram RD, Caikovski M, Ayyanan
A, Germano D, Choi Y, Schneider P and Brisken C: Two distinct
mechanisms underlie progesterone-induced proliferation in the
mammary gland. Proc Natl Acad Sci USA. 107:2989–2994. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Armstrong AP, Tometsko ME, Glaccum M,
Sutherland CL, Cosman D and Dougall WC: A RANK/TRAF6-dependent
signal transduction pathway is essential for osteoclast
cytoskeletal organization and resorptive function. J Biol Chem.
277:44347–44356. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Darnay BG, Haridas V, Ni J, Moore PA and
Aggarwal BB: Characterization of the intracellular domain of
receptor activator of NF-kappaB (RANK). Interaction with tumor
necrosis factor receptor-associated factors and activation of
NF-kappaB and c-Jun N-terminal kinase. J Biol Chem.
273:20551–20555. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mori K, Le Goff B, Berreur M, Riet A,
Moreau A, Blanchard F, Chevalier C, Guisle-Marsollier I, Léger J,
Guicheux J, et al: Human osteosarcoma cells express functional
receptor activator of nuclear factor-kappa B. J Pathol.
211:555–562. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu
J, Hou K, Yang X, Liu Y and Qu X: C-Src-mediated RANKL-induced
breast cancer cell migration by activation of the ERK and Akt
pathway. Oncol Lett. 3:395–400. 2012.PubMed/NCBI
|
|
11
|
Gonzalez-Suarez E, Jacob AP, Jones J,
Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D and
Dougall WC: RANK ligand mediates progestin-induced mammary
epithelial proliferation and carcinogenesis. Nature. 468:103–107.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schramek D, Leibbrandt A, Sigl V, Kenner
L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A,
Glimcher L, et al: Osteoclast differentiation factor RANKL controls
development of progestin-driven mammary cancer. Nature. 468:98–102.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Palafox M, Ferrer I, Pellegrini P, Vila S,
Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Muñoz P,
Viñals F, et al: RANK induces epithelial-mesenchymal transition and
stemness in human mammary epithelial cells and promotes
tumorigenesis and metastasis. Cancer Res. 72:2879–2888. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schramek D, Sigl V and Penninger JM: RANKL
and RANK in sex hormone-induced breast cancer and breast cancer
metastasis. Trends Endocrinol Metab. 22:188–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Santini D, Schiavon G, Vincenzi B, Gaeta
L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, et
al: Receptor activator of NF-kB (RANK) expression in primary tumors
associates with bone metastasis occurrence in breast cancer
patients. PLoS One. 6:e192342011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dai D, Wolf DM, Litman ES, White MJ and
Leslie KK: Progesterone inhibits human endometrial cancer cell
growth and invasiveness: down-regulation of cellular adhesion
molecules through progesterone B receptors. Cancer Res. 62:881–886.
2002.PubMed/NCBI
|
|
17
|
Leslie KK, Kumar NS, Richer J, Owen G,
Takimoto G, Horwitz KB and Lange C: Differential expression of the
A and B isoforms of progesterone receptor in human endometrial
cancer cells. Only progesterone receptor B is induced by estrogen
and associated with strong transcriptional activation. Ann NY Acad
Sci. 828:17–26. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ai ZH, Wang J, Wang YD, Lu LH, Tong JQ and
Teng YC: Overexpressed epidermal growth factor receptor
(EGFR)-induced progestin insensitivity in human endometrial
carcinoma cells by the EGFR/mitogen-activated protein kinase
signaling pathway. Cancer. 116:3603–3613. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jones DH, Nakashima T, Sanchez OH,
Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R,
Hojilla CV, et al: Regulation of cancer cell migration and bone
metastasis by RANKL. Nature. 440:692–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Armstrong AP, Miller RE, Jones JC, Zhang
J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing
prostate tumor cells and mediates migration and expression of tumor
metastasis genes. Prostate. 68:92–104. 2008. View Article : Google Scholar
|
|
21
|
Mori K, Le Goff B, Charrier C, Battaglia
S, Heymann D and Rédini F: DU145 human prostate cancer cells
express functional receptor activator of NFkappaB: new insights in
the prostate cancer bone metastasis process. Bone. 40:981–990.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wittrant Y, Théoleyre S, Chipoy C,
Padrines M, Blanchard F, Heymann D and Rédini F: RANKL/RANK/OPG:
new therapeutic targets in bone tumours and associated osteolysis.
Biochim Biophys Acta. 1704:49–57. 2004.PubMed/NCBI
|
|
23
|
Nebreda AR and Porras A: p38 MAP kinases:
beyond the stress response. Trends Biochem Sci. 25:257–260. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schieven GL: The biology of p38 kinase: a
central role in inflammation. Curr Top Med Chem. 5:921–928. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Manning AM and Davis RJ: Targeting JNK for
therapeutic benefit: from junk togold? Nat Rev Drug Discov.
2:554–565. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto Y and Gaynor RB: Therapeutic
potential of inhibition of the NF-kappaB pathway in the treatment
of inflammation and cancer. J Clin Invest. 107:135–142. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barkett M and Gilmore TD: Control of
apoptosis by Rel/NFkappaB transcription factors. Oncogene.
18:6910–6924. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hashimoto I, Koizumi K, Tatematsu M,
Minami T, Cho S, Takeno N, Nakashima A, Sakurai H, Saito S, Tsukada
K and Saiki I: Blocking on the CXCR4/mTOR signaling pathway induces
the anti-metastatic properties and autophagic cell death in
peritoneal disseminated gastric cancer cells. Eur J Cancer.
44:1022–1029. 2008. View Article : Google Scholar : PubMed/NCBI
|
